Accord Healthcare has received FDA approval for its intravenous atropine sulfate generic under ANDA212868, a move likely to strengthen the company’s foothold in the hospitals and ambulatory surgical center markets. This clearance positions Accord to compete with branded drugmakers, increasing available options for cost-conscious healthcare providers in the critical care sector.